Your latest round-up

When the pandemic was declared, several synthetic biology companies pivoted from developing vaccines for other viruses to focus on COVID-19. If a synbio company is the first, or among the first to end the COVID-19 pandemic, it will be a dramatic debut for this game-changing new technology.

The spotlight will be on synthetic biology if it ends the pandemic and identifies viral threats in crowded spaces.

EYQ |7 minute read
Even as they deal with the immediate impact of COVID-19, organizations should be thinking about how they’ll thrive in a post-pandemic world.

Andy Baldwin
More on responding to COVID-19
Explore other themes
More of our latest Tweets
LinkedIn  Twitter  Facebook  YouTube
Unsubscribe from list | Unsubscribe from all marketing communications

EY | Assurance | Tax | Transactions | Advisory

About EY

EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit

© 2020 EYGM Limited.
All Rights Reserved.

This material has been prepared for general informational purposes only and is not intended to be relied upon as accounting, tax or other professional advice. Please refer to your advisors for specific advice.